5 New “Cluster-Based” Classifications of Diabetes

Weekly Dose Podcast: FDA Breakthrough in Acromegaly, Alcohol–Dementia Risk Clarified, Tirzepatide in Youth T2D, Precision Mood Gains, and Major Contraception Practice Insights

Topline Phase 3 ATTAIN-MAINTAIN data show oral orforglipron met primary and key secondary endpoints for weight maintenance after prior GLP-1–based injectable therapy in adults with obesity.

November 19th 2025

When Daily Oral PrEP Is Not the Best Fit: Lessons From Clinical Practice

Topics include new findings on oral acromegaly therapy, alcohol and dementia risk, tirzepatide in youth T2D, precision mood care, and LARC outcomes.

Kevin Hatfield, MD;Sydney Jennings

Weekly Dose Podcast: New Insights on Colonoscopy Adherence, rt-CGM in GDM, Semaglutide Effects, Parent Vaccine Views, and MI Causes

Real-world patient cases illustrating how pill burden, privacy, and individual preferences influence PrEP selection and adherence.

November 13th 2025

Tezepelumab Achieves Dual Benefit in Adults with Severe Asthma: Daily Dose

Topics include rideshare support for colonoscopy, rt-CGM benefits in GDM, semaglutide and food noise, vaccine views, and MI etiology.

FDA Approves Lerodalcibep, Third-Generation PCSK9 Inhibitor, to Treat Hypercholesterolemia, Including HeFH

Your daily dose of the clinical news you may have missed.

Grace Halsey

Phase 3 Data Support Oral Orforglipron for Weight Maintenance After GLP-1–Based Weight Loss

Phase 3 LIBerate data showed sustained LDL-C reductions of 60% or more in high-risk patients and 50% or more in HeFH, with once-monthly self-administration.

Related Content

Weekly Dose Podcast: FDA Breakthrough in Acromegaly, Alcohol–Dementia Risk Clarified, Tirzepatide in Youth T2D, Precision Mood Gains, and Major Contraception Practice Insights

Topline Phase 3 ATTAIN-MAINTAIN data show oral orforglipron met primary and key secondary endpoints for weight maintenance after prior GLP-1–based injectable therapy in adults with obesity.

November 19th 2025

When Daily Oral PrEP Is Not the Best Fit: Lessons From Clinical Practice

Topics include new findings on oral acromegaly therapy, alcohol and dementia risk, tirzepatide in youth T2D, precision mood care, and LARC outcomes.

Kevin Hatfield, MD;Sydney Jennings

Weekly Dose Podcast: New Insights on Colonoscopy Adherence, rt-CGM in GDM, Semaglutide Effects, Parent Vaccine Views, and MI Causes

Real-world patient cases illustrating how pill burden, privacy, and individual preferences influence PrEP selection and adherence.

November 13th 2025

Tezepelumab Achieves Dual Benefit in Adults with Severe Asthma: Daily Dose

Topics include rideshare support for colonoscopy, rt-CGM benefits in GDM, semaglutide and food noise, vaccine views, and MI etiology.

FDA Approves Lerodalcibep, Third-Generation PCSK9 Inhibitor, to Treat Hypercholesterolemia, Including HeFH

Your daily dose of the clinical news you may have missed.

Grace Halsey